Expert Review of Pharmacoeconomics and Outcomes Research 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore
CONCLUSION: At its current price, sacituzumab govitecan does not represent a cost-effective treatment for relapsed or refractory metastatic TNBC in Singapore. Our findings will be useful to inform funding decisions alongside other factors including clinical effectiveness, safety, and budget impact considerations.PMID:38149409 | DOI:10.1080/14737167.2023.2291155 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 27, 2023 Category: Health Management Authors: Boon Piang Cher Sharon Goh Mohamed Ismail Abdul Aziz Grace Wong Raymond Ng Chee Hui Benjamin Shao-Kiat Ong Kwong-Hoe Ng Source Type: research
What to expect in 2024: important health economics and outcomes research (HEOR) trends
Expert Rev Pharmacoecon Outcomes Res. 2023 Dec 21:1-8. doi: 10.1080/14737167.2023.2292838. Online ahead of print.NO ABSTRACTPMID:38126707 | DOI:10.1080/14737167.2023.2292838 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 21, 2023 Category: Health Management Authors: Ivo Abraham Mickael Hiligsmann Kenneth K C Lee Leslie Citrome Giorgio L Colombo Mike Gregg Source Type: research
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain
CONCLUSIONS: Avacopan is a cost-effective option for patients with severe, active AAV compared to GC in Spain.PMID:38126738 | DOI:10.1080/14737167.2023.2297790 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 21, 2023 Category: Health Management Authors: Manuel Mac ía Montserrat D íaz-Encarnación Roser Solans-Laqu é Elisenda Pomares Mallol Alejandra Garc ía Castells Cristina Escribano Antonio Ram írez de Arellano Source Type: research
What to expect in 2024: important health economics and outcomes research (HEOR) trends
Expert Rev Pharmacoecon Outcomes Res. 2023 Dec 21:1-8. doi: 10.1080/14737167.2023.2292838. Online ahead of print.NO ABSTRACTPMID:38126707 | DOI:10.1080/14737167.2023.2292838 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 21, 2023 Category: Health Management Authors: Ivo Abraham Mickael Hiligsmann Kenneth K C Lee Leslie Citrome Giorgio L Colombo Mike Gregg Source Type: research
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain
CONCLUSIONS: Avacopan is a cost-effective option for patients with severe, active AAV compared to GC in Spain.PMID:38126738 | DOI:10.1080/14737167.2023.2297790 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 21, 2023 Category: Health Management Authors: Manuel Mac ía Montserrat D íaz-Encarnación Roser Solans-Laqu é Elisenda Pomares Mallol Alejandra Garc ía Castells Cristina Escribano Antonio Ram írez de Arellano Source Type: research
What to expect in 2024: important health economics and outcomes research (HEOR) trends
Expert Rev Pharmacoecon Outcomes Res. 2023 Dec 21:1-8. doi: 10.1080/14737167.2023.2292838. Online ahead of print.NO ABSTRACTPMID:38126707 | DOI:10.1080/14737167.2023.2292838 (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - December 21, 2023 Category: Health Management Authors: Ivo Abraham Mickael Hiligsmann Kenneth K C Lee Leslie Citrome Giorgio L Colombo Mike Gregg Source Type: research
